Click here


FRACT — The Global Research Infrastructure for Psychedelic & Cannabis Medicine

FRACT connects psychedelic, cannabis, and natural-medicine companies with universities, clinical partners, and qualified investors through a compliant framework for research, clinical trials, and commercialisation. From protocol design and ethics coordination to capital formation, milestone governance, and IP administration, FRACT provides the infrastructure required to move serious medical research from concept to execution. Built for the next generation of regulated medicine.

Project Application

Structured for: Psychedelics • Cannabis • Natural Medicines • Functional Compounds • Clinical Research • Preventative Medicine

Supported by the wider Hollograf Group ecosystem, including: Hollograf Institute • Institute of Psychedelic Medicines • Hollograf Labs

© FRACT.co 2025

The Problem

The psychedelic and cannabinoid sectors are entering a new phase of legitimacy. Regulatory pathways are evolving. Institutional interest is growing. Clinical demand is accelerating globally.

Yet most companies still face the same structural barriers:

  • Fragmented clinical infrastructure
  • Slow ethics pathways
  • Disconnected funding channels
  • Unclear IP structures
  • Limited investor confidence
  • Cross-border regulatory complexity
  • Escalating trial costs

At the same time, the recent evolution of U.S. cannabis scheduling policy is expected to accelerate demand for cannabinoid clinical studies, product validation, and evidence-based commercialisation. Most operators are not prepared for this transition.

FRACT was built to solve that problem.

© FRACT.co 2025

What Is FRACT

A Cross-Border Research & Commercialisation Platform

FRACT is a decentralised research exchange designed to help companies structure, fund, and execute compliant research programs in psychedelic and cannabis medicine. The platform connects:

  • Biotechnology companies
  • Psychedelic medicine developers
  • Cannabis brands and formulators
  • Universities and research institutions
  • CROs and clinical sites
  • Strategic investors and family offices

Capital & Custody (USA)

Regulated Delaware fundraising structures combined with licensed custodial escrow services ensure investor protection and regulatory compliance.

R&D Control (Australia)

Comprehensive ethics governance frameworks and rigorous research oversight maintained through Australian regulatory standards.

Field Operations (Thailand)

Efficient patient recruitment protocols and professionally managed clinical site coordination within compliant Thai facilities.

IP Licensing (Canada)

Post-trial intellectual property administration and commercial licensing managed through transparent Canadian frameworks.

FRACT provides the operational layer between scientific ambition and real-world execution.

© FRACT.co 2025

What FRACT Actually Does

From Research Proposal to Commercialisation

FRACT is designed to manage the entire lifecycle of a research initiative.

For Brands

Transform products or molecular compounds into regulator-ready clinical evidence through professional research governance, transparent reporting mechanisms, and streamlined compliance pathways. We handle the complexity of multi-jurisdictional trials whilst you maintain focus on product development and commercialisation strategy.

For Researchers

Access non-dilutive funding opportunities without sacrificing equity or institutional autonomy. Benefit from clearly defined data rights, comprehensive ethics support, and transparent execution frameworks that accelerate research timelines whilst maintaining academic rigour and publication freedom.

For Investors

Participate in psychedelic and cannabis research on a per-project basis using verified milestone tracking, licensed escrow protection, and auditable documentation systems. Gain exposure to emerging therapeutic compounds with clear risk assessment and transparent capital deployment schedules.

For Regulators

Receive consistent, comprehensive documentation packages from initial proposal through final analysis. Our standardised reporting frameworks simplify regulatory review processes and ensure compliance across international jurisdictions.

FRACT acts as the infrastructure layer that aligns all stakeholders into one coordinated system.

© FRACT.co 2025

How It Works

FRACT's streamlined process transforms research concepts into commercially viable clinical evidence through transparent, milestone-based execution.

Apply

Submit your project proposal on fract.co with clearly defined endpoints, study design specifications, and preliminary budget estimates. A project application fee of US$25,000 is required. This covers preliminary project assessment, feasibility and budget review, advisory screening, protocol and commercialisation analysis, preliminary investor readiness evaluation, and jurisdictional pathway assessment.

Advisory Review

Independent scientific, regulatory, and commercial assessment through FRACT's advisory network evaluates project merit, feasibility, and compliance requirements.

Project Structuring

Research design support, protocol refinement, budget modelling, and feasibility analysis. FRACT produces comprehensive investor dossiers and governance frameworks tailored to your research objectives.

Capital Coordination

Approved projects are introduced to qualified investors, strategic partners, and co-development structures through secure, compliant channels with full disclosure documentation.

Funding & Escrow

Investors commit capital via Delaware Series vehicles; funds are held in licensed custodial escrow with transparent release conditions tied to verified milestone completion.

Ethics & Governance

Coordination with universities, ethics committees, CROs, and jurisdictional advisors. Partner institutions conduct studies under approved ethics protocols with ongoing quality oversight.

Clinical Execution

Cross-border management of recruitment, operations, milestone tracking, and reporting. All critical events receive tamper-evident digital timestamps.

IP & Commercialisation

Resulting intellectual property is licensed to project sponsors with ongoing performance reporting, transparent royalty administration, and long-term commercial strategy.

© FRACT.co 2025

Why Now

Psychedelic & Cannabis Medicine Are Entering an Institutional Era

The market is shifting rapidly from speculative wellness into evidence-based medicine. Three major transitions are happening simultaneously:

Clinical Validation

Regulators, healthcare systems, and investors increasingly require clinical evidence and measurable outcomes.

Cannabis Reclassification Momentum

Recent U.S. policy shifts surrounding cannabis scheduling are expected to increase demand for formal research pathways, product validation, and pharmaceutical-grade data.

AI & Data-Driven Healthcare

Research, diagnostics, patient tracking, and clinical analytics are becoming more integrated and measurable.

The next generation of category leaders will not simply sell products. They will own validated data, clinical outcomes, and defensible intellectual property.

© FRACT.co 2025

Who FRACT Is Built For

Designed for Serious Operators

FRACT is built for operators who are serious about clinical evidence, regulatory compliance, and long-term commercialisation.

Psychedelic Medicine Companies

Seeking clinical validation, protocol support, and institutional credibility.

Cannabis & Cannabinoid Brands

Preparing for evidence-driven regulatory and pharmaceutical markets.

Universities & Research Institutions

Looking for funding pathways and industry collaboration.

Investors & Strategic Partners

Seeking structured exposure to emerging regulated medicine sectors.

Clinics & CROs

Participating in scalable, cross-border clinical programs.

FRACT compresses the timeline to clinical credibility by providing an integrated operational framework from day one.

© FRACT.co 2025

The FRACT Model

A Multi-Jurisdictional Research Framework

FRACT operates through a specialised international structure designed to optimise governance, compliance, execution, and IP management. This structure enables serious companies to access a globally coordinated research pathway without building the infrastructure internally.

🇺🇸 United States

Capital formation, investor structures, regulated escrow, and governance frameworks.

🇦🇺 Australia

Research governance, ethics pathways, university partnerships, and clinical oversight.

🇹🇭 Thailand

Clinical operations, patient recruitment, natural-medicine infrastructure, and cost-efficient execution.

🇨🇦 Canada

Intellectual property administration, licensing, and royalty management.

This structure enables serious companies to access a globally coordinated research pathway without building the infrastructure internally.

© FRACT.co 2025

Why Companies Use FRACT

Building Clinical Infrastructure Internally Is Expensive

Most emerging companies do not have:

  • Cross-border regulatory expertise
  • University relationships
  • Ethics coordination capacity
  • Investor networks
  • Milestone governance systems
  • IP commercialisation structures

Building this independently can take years. FRACT compresses that timeline by providing an integrated operational framework from day one.

FRACT operates through a specialised international structure:

The FRACT Infrastructure

Regulated fundraising vehicles structured as Delaware Series entities, combined with licensed custodial escrow services providing investor protection and capital security under US securities regulations.

Australia

Comprehensive ethics frameworks administered through Australian institutional review boards, research oversight mechanisms, and governance documentation compliant with National Health and Medical Research Council standards.

Thailand

Clinical site operations conducted under Thai Food and Drug Administration and Department of Thai Traditional and Alternative Medicine requirements, ensuring patient safety and regulatory compliance for all trial activities.

Canada

Intellectual property holding structures and licensing administration managed through Canadian frameworks with transparent reporting mechanisms and contractual governance.

© FRACT.co 2025

The Hollograf Ecosystem

Part of the Wider Hollograf Group

FRACT operates within the broader Hollograf ecosystem focused on psychedelic medicine, education, AI, and regulated health innovation.

Hollograf Institute

Education, practitioner training, and psychedelic medicine programs.

Institute of Psychedelic Medicines

Clinical and professional education initiatives.

Hollograf Labs

Research, analytics, formulation science, and future molecule development.

Hollograf Clinic

Virtual and physical psychedelic-assisted therapy services, delivering regulated therapeutic programs to patients globally.

Together, the ecosystem is designed to support the evolution of regulated psychedelic and cannabinoid medicine globally.

© FRACT.co 2025

Compliance & Positioning

Built for Long-Term Legitimacy

FRACT is designed around transparency, governance, and responsible research execution. The platform is structured to support:

  • Compliant clinical coordination
  • Documented milestone tracking
  • Independent oversight
  • Long-term IP administration
  • Institution-grade reporting standards

Compliant Coordination

Structured multi-jurisdictional framework leveraging each country's regulatory strengths

Milestone Governance

Auditable, tamper-evident tracking of all critical research and funding events

Independent Oversight

Advisory board review and ethics committee coordination across all projects

IP Administration

Transparent licensing frameworks and royalty management post-trial

Institution-Grade Reporting

Standardised documentation packages for regulators, investors, and partners

FRACT does not provide medical advice, securities advice, or guarantee funding outcomes.

© FRACT.co 2025

Frequently Asked Questions

Is FRACT a fund?

No. FRACT operates as a curated platform providing research governance infrastructure and compliant project funding coordination. We facilitate connections between research opportunities and qualified investors but do not pool capital or make investment decisions on behalf of participants.

Who conducts the research?

Research activities are performed by accredited universities and contract research organisations possessing appropriate ethics approvals, regulatory permissions, and institutional capabilities. FRACT provides governance oversight but does not directly conduct clinical trials or laboratory investigations.

Does FRACT guarantee project funding?

No. FRACT packages projects for investor consideration through comprehensive due diligence and professional documentation. Funding decisions remain separate and are subject to investor discretion, regulatory requirements, and risk assessment independent of FRACT's operational role.

Who owns the intellectual property?

Intellectual property ownership and licensing arrangements depend on specific project contracts negotiated between sponsors, research institutions, and investors. FRACT administers post-trial licensing transparently per contractual agreements but does not claim ownership of research outputs.

What is the application fee?

The initial application fee is US$25,000. This covers preliminary project assessment, feasibility and budget review, advisory screening, protocol and commercialisation analysis, preliminary investor readiness evaluation, and jurisdictional pathway assessment. Submission does not guarantee funding, approval, or project acceptance.

What qualifications are required for investors?

Investment participation requires accreditation status under applicable securities regulations and completion of jurisdiction-specific qualification procedures. Requirements vary by location and are detailed in separate offering documentation provided to qualified parties.

© FRACT.co 2025

Contact

Get in Touch

Whether you represent a brand with promising compounds, a university research team, a qualified investor, or a regulatory body seeking information, we welcome enquiries about FRACT's governance frameworks and project opportunities.

Headquarters

Delaware, United States of America

Global Operations

Australia • Thailand • Canada

Email

invest@fract.co

Our international team typically responds to enquiries within 48 business hours. For project submissions, please use the application portal at fract.co to ensure proper routing and documentation.

© FRACT.co 2025

Legal Disclaimer

This website is provided for informational purposes only and does not constitute an offer to sell securities, medical advice, legal advice, or investment solicitation. Participation in any research or investment opportunity is subject to separate agreements, regulatory requirements, and jurisdictional eligibility.

FRACT does not provide legal advice, tax guidance, or financial recommendations. Prospective participants should consult qualified independent advisors regarding suitability, risk factors, and regulatory implications relevant to their specific circumstances and jurisdictions.

Forward-looking statements regarding research outcomes, commercialisation potential, or therapeutic applications involve inherent uncertainties and should not be construed as guarantees of future results. Psychedelic and cannabis research remains subject to evolving regulatory landscapes and scientific validation processes.

All forward-looking statements are subject to risks and uncertainties. All trademarks, service marks, and trade names referenced are property of their respective owners. Unauthorised reproduction or distribution of website content is prohibited.

© FRACT.co 2025

Privacy & Data Protection

FRACT maintains rigorous data protection standards consistent with international privacy regulations including GDPR, PIPEDA, and applicable US state privacy laws. We implement comprehensive technical and organisational measures to safeguard sensitive research data, personal information, and commercial intellectual property.

Data Protection Principles

  • Purpose limitation and minimal data collection protocols
  • Encryption for data in transit and at rest
  • Role-based access controls with audit logging
  • Regular security assessments and penetration testing
  • Incident response procedures and breach notification protocols
  • Data retention policies aligned with regulatory requirements

Research participants' personal information is handled in strict accordance with ethics protocols and applicable privacy legislation. Clinical data transfers across jurisdictions comply with international data protection frameworks.

For detailed information regarding data processing activities, please review our complete Privacy Policy available at fract.co/privacy or contact our data protection officer at privacy@fract.co.

© FRACT.co 2025

Join the FRACT Network

FRACT is building the infrastructure for the next generation of psychedelic and cannabis medicine research. We invite qualified stakeholders to explore partnership opportunities and participate in advancing evidence-based therapeutic development.

Research Institutions

Universities and contract research organisations seeking non-dilutive funding, streamlined governance, and transparent project execution frameworks.

Commercial Sponsors

Brands with promising compounds requiring regulator-ready evidence, professional research governance, and compliant clinical trial execution.

Qualified Investors

Accredited investors seeking exposure to psychedelic and cannabis research opportunities with transparent milestone tracking and regulated governance structures.

Our growing network spans multiple continents and therapeutic areas, united by commitment to scientific rigour, ethical excellence, and transparent stakeholder communication.

© FRACT.co 2025

Building the Future of Psychedelic & Cannabis Research Infrastructure

Whether you are developing:

  • Psychedelic therapies
  • Cannabinoid medicines
  • Functional compounds
  • Preventative health solutions
  • Clinical research initiatives

FRACT provides the infrastructure to help serious projects move forward.

Our Vision

Creating the foundational infrastructure layer that enables psychedelic and cannabis research to scale responsibly, accelerating therapeutic development whilst maintaining unwavering commitment to scientific integrity, patient safety, and transparent communication.

Our Mission

Connecting research capability with commercial capital through compliant, transparent governance frameworks that serve brands, universities, investors, and regulators across multiple jurisdictions.

The next generation of category leaders will own validated data, clinical outcomes, and defensible intellectual property. FRACT exists to make that possible.

🌐 fract.co
📧 invest@fract.co
Part of the Hollograf Group
© FRACT.co 2025